Raymond James Downgrades Exact Sciences (EXAS) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Exact Sciences (EXAS) PT Lowered to $125 at Stifel
November 3, 2021 6:44 AM EDTStifel analyst Daniel Arias lowered the price target on Exact Sciences (NASDAQ: EXAS) to $125.00 (from $145.00) while maintaining a Buy rating.
The analyst commented, "EXAS's 3Q saw the company miss on Screening (Cologuard) revenues, and lower the outlook for 4Q - as... More



